REG - Cambridge Cognition - Director/PDMR Share Purchases

Cambridge Cognition HoldingsAnnouncement

23/12/2024 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241223:nRSW1766Ra&default-theme=true

RNS Number : 1766R  Cambridge Cognition Holdings PLC  23 December 2024

23 December 2024

Cambridge Cognition Holdings Plc

("Cambridge Cognition", the "Company" or the "Group")

Director/PDMR Share Purchases

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets
digital solutions to assess brain health, was informed on 23 December 2024
that Nick Rodgers, Non-Executive Director of the Company, purchased 31,292
ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a
price of 31.88 pence per share.

Following this transaction, Nick Rodgers holds an interest in 51,292 Ordinary
Shares, representing approximately 0.12% of the Company's issued share
capital.

Further information on the purchases is contained in the disclosure tables
below.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Nick Rodgers
 2    Reason for the notification
 a)   Position/status                                              Non-Executive Director
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Cambridge Cognition Holdings Plc
 b)   LEI                                                          213800SZKDIN122EPA96
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares of 0.01p each

      Identification code

                                                                   GB00B8DV9647
 b)   Nature of the transaction                                    Purchase of Shares
 c)   Price(s) and volume(s)                                         Price(s)    Volume(s)
                                                                   31.8 pence    18,830
                                                                   32.0 pence    12,462

 
 d)   Aggregated information

      - Aggregated volume                                          31,292

      - Price                                                      31.88
 e)   Date of the transaction                                      23 December 2024
 f)   Place of the transaction                                     London Stock Exchange

 

d)

Aggregated information

- Aggregated volume

- Price

 

31,292

31.88

e)

Date of the transaction

23 December 2024

f)

Place of the transaction

London Stock Exchange

 

 

Enquiries:

 Cambridge Cognition Holdings plc                    Tel: 012 2381 0700

 Dr Steven Powell, Chairman

 Hudson Sandler (Financial PR and IR)                Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Harry Griffiths    cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)    Tel: 020 7886 2968

 Will Goode / Freddy Crossley / Mark Rogers          (Corporate Finance)

 Rupert Dearden                                      (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)

 David Poutney / James Serjeant                      Tel: 020 3903 7715

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a leading technology company specializing in digital
health products that advance brain health research and treatment. The Company
offers three core products: CANTAB® assessments, which provide scientifically
validated, highly sensitive, precise, and objective measures of cognitive
function correlated to neural networks; a flexible and proven eCOA platform,
with a large library of instruments, enabling efficient study set up and
scalable data capture; and Quality Assurance Tools that ensure data integrity
by automatically detecting deviations in administration and scoring, saving
time and money. Together, these products improve clinical trial outcomes,
enable early patient identification, and enhance global efficiency in
healthcare and pharmaceuticals.

For further information visit: https://cambridgecognition.com/
(https://cambridgecognition.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPGGUPUPCGQW